Rating Change
Guggenheim reiterated its Buy rating on ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) on August 13, 2026.
reiterateNASDAQ:AVBP
Guggenheim Reiterates Buy Rating on ArriVent BioPharma, Inc. Common Stock (AVBP)
Guggenheim reiterated its Buy rating on ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) on August 13, 2026.
At publication ·
What changed
ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) · reiterate
- Firm
- Guggenheim
- Rating
- Buy to Buy
- Price at event
- $30.00
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Guggenheim reiterated a Buy rating on ArriVent BioPharma (AVBP) on August 13, 2026, with the stock trading at $30.00 and a market capitalization of $1.0 billion.
Market Context
ArriVent BioPharma, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $30.00 with a market capitalization of $1.0B. The stock has gained 56.2% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ArriVent BioPharma, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ArriVent BioPharma, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 13, 2026 | Citigroup | Buy | N/A |
| Aug 13, 2026 | Guggenheim | Buy | N/A |
| Aug 13, 2026 | BTIG | Buy | N/A |
| May 29, 2026 | Truist Securities | Buy | N/A |
| May 13, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AVBP Stock Page
Frequently Asked Questions
What does the Buy rating mean for AVBP?
A rating of Buy from Guggenheim reflects the analyst's outlook on ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AVBP forecast page.
